BioSpace News Archive

Biohaven Pharmaceutical Holding Company Ltd. reported topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder.

Samsara BioCapital, a leading life sciences investment firm, Evotec SE, a global drug discovery alliance and development partnership company, and KCK Ltd., a family investment fund, announced the launch of Autobahn Labs, a novel virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in it

Attracting one of med-tech’s most accomplished executives, Aldevron has named Kevin Ballinger as Chief Executive Officer, effective July 13, 2020.

Encompass Health Corp. announced it will report results for its second quarter ending June 30, 2020, after the market closes on July 27, 2020.

HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct a phase 2 clinical trial of HST5040, an oral small molecule drug for the treatment of patients

First Human-Derived Antibody with the Potential to Treat Multiple Cancers Reaches the Clinic

Includes positive clinical findings from a postcoital test (PCT) human clinical study of Ovaprene®, an investigational hormone-free, monthly contraceptive

-- Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation – -- Both weekly and daily formulations of setmelanotide were observed to be safe and well-tolerated – -- Pharmacokinetics analysis showed weekly formulation of setmelanotide trough drug concentration similar to daily formulation –

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373. Fireside chat details ar